Find Academic Supervisors

Jennifer L Hsiao is a Clinical Associate Professor of Dermatology at the University of Southern California. Her work focuses on hidradenitis suppurativa (HS), particularly in special populations including pregnancy, pediatrics, and patients with comorbid autoimmune conditions. She has contributed to developing clinical practice guidelines, safety analyses of biologic therapies, and patient-centered care strategies. Her research explores HS pathogenesis, treatment adherence, and disparities in clinical trial representation. Notable contributions include consensus statements on diagnostic criteria for cutaneous Crohn's disease, management algorithms for HS, and safety reviews of JAK inhibitors and TNF-alpha antagonists. Dr. Hsiao emphasizes translational research, bridging clinical practice with health policy. She has examined NIH dermatology funding trends, dermatology access disparities in Los Angeles, and allergen analysis of skincare products. Her work often integrates patient perspectives, including surveys on diagnosis challenges, treatment barriers, and quality-of-life impacts. She collaborates internationally on HS research through initiatives like the Asia Pacific Hidradenitis Suppurativa (APHiS) foundation and has contributed to over 200 peer-reviewed publications since 2007. Her academic activities include teaching, mentoring, and advancing dermatological education through innovative clinical approaches.

• Dermatology
• Hidradenitis Suppurativa
• Clinical Research
• +5 more

Shafali Jeste is a Professor of Neurology and Pediatrics at the University of Southern California, where she also serves as Division Chief of Neurology and Co-Director of the Neurological Institute at Children's Hospital Los Angeles (CHLA). Her academic and clinical work is centered at the intersection of pediatric neurology and neurodevelopmental disorders, with a strong commitment to translational research that bridges basic science and clinical application. Dr. Jeste's research program is dedicated to understanding the neurobiological underpinnings of autism spectrum disorder (ASD), epilepsy, and related genetic syndromes such as Dup15q and Tuberous Sclerosis Complex. She employs electrophysiological techniques, particularly EEG, to identify biomarkers for diagnosis and treatment monitoring. Her work also integrates genomic data to inform neuropsychiatric care and improve diagnostic pathways for children with neurogenetic conditions. This multidisciplinary approach involves collaboration across neurology, genetics, psychiatry, and statistics. Analysis of her recent publications (2023-2025) indicates a consistent emphasis on characterizing the clinical and electrophysiological profiles of specific neurogenetic disorders, optimizing diagnostic processes, and developing objective biomarkers for clinical trials. Her research increasingly incorporates advanced statistical methods for analyzing complex neurophysiological data, reflecting a growing trend toward computational neuroscience in her field. Dr. Jeste co-directs the Neurological Institute at CHLA and leads the Autism Biomarkers Consortium for Clinical Trials, a collaborative initiative aimed at validating EEG biomarkers for autism to accelerate therapeutic development. While specific details about her laboratory and team composition are not provided, her leadership roles suggest oversight of a multidisciplinary research group.

• Autism Spectrum Disorder
• Epilepsy
• Neurogenetics
• +3 more

Åsmund Flobak is an Associate Professor at the Norwegian University of Science and Technology, where he leads the FlobakLab and serves as Principal Investigator for the IMPRESS-Norway clinical trial. His research integrates wet-lab experiments and computational modeling to predict drug responses in cancer. Education includes: Medical Doctor (2005) MSc Nanotechnology (2013) PhD in Systems Medicine (2016) His research focuses on systems medicine approaches to cancer treatment, developing the DrugLogics pipeline for drug synergy prediction. Work combines logical modeling of signaling networks with high-throughput drug screening in patient-derived cells. Publications demonstrate consistent focus on computational oncology, with themes including: Boolean network modeling of drug interactions High-throughput combination screening platforms Nanotechnology applications in drug delivery Awards and Honors: Medical Teaching Award, Norwegian Medical Association (2024) Lecturer of the Year, NTNU Medical Students (2019, 2023) Current projects include: PRESORT (RCN-funded drug response prediction) OncoLogics (EU PerMed consortium) COLOGIC (3D patient-derived tumor models) Lab comprises 5 PhD candidates and postdoctoral researchers investigating precision oncology approaches.

• Systems Medicine
• Drug Synergy Prediction
• Cancer Research
• +3 more

Abdullah Albizri is an Associate Professor of Information Management & Business Analytics at the Feliciano School of Business, Montclair State University. His academic journey includes a PhD in Management Information Systems from the University of Wisconsin, an MBA and BS from Lebanese American University. He has held roles such as Strategic Planning Officer at BLOM Bank and academic positions at Northern State University and Montclair State University. Albizri's research focuses on AI applications in healthcare, energy, and finance, including fraud detection, electricity consumption forecasting, and blockchain smart contract auditing. He explores how technology can address societal challenges like organ donation crises and opioid overdose emergencies through AI-driven solutions. His work emphasizes interdisciplinary approaches, integrating human knowledge with artificial intelligence for complex problem-solving. Education: PhD, Management Information Systems, University of Wisconsin MBA, Lebanese American University BS, Lebanese American University His research has been recognized through awards like the Nora Staael Evert Research Award (2015) and the Best Paper Award at the 2019 Information and Communication Technologies Conference. Albizri's publications span journals like Communications of the Association for Information Systems and Annals of Operations Research , with a focus on AI ethics, healthcare analytics, and energy systems. He actively contributes to bridging academia and industry through curriculum design for business analytics practitioners.

• Data Mining
• Artificial Intelligence
• Electricity Consumption Feedback
• +6 more

Somaya Ben Allouch is a Full Professor specializing in digital life and applied research through the CREATE-IT initiative. Her work focuses on human-centered AI, healthcare technology, and assistive systems for vulnerable populations such as the elderly and patients with dementia. She holds a PhD in a relevant field but her academic institution affiliation is not explicitly stated in the provided materials. Her research interests span social robotics, digital nature interventions, smoking cessation technologies, and personalized healthcare solutions. Notable projects include developing AI-driven dementia care frameworks, studying smart glasses in healthcare, and creating child-robot educational systems. Dr. Ben Allouch has received awards including the Best Studies Paper Award (2023) and the SO-NUTS research grant (2020). She actively participates in organizing academic events like the HHAI conference and contributes to interdisciplinary collaborations bridging design, AI, and healthcare. Her recent publications (2020-2024) emphasize machine learning applications in healthcare, human-robot interaction, and technology acceptance studies. Key themes include long-term neurocognitive outcome prediction, blended treatment modalities for smoking cessation, and ethical AI integration in medical settings.

• Digital Nature
• Social Robots
• Healthcare Technology
• +4 more

Assoc. Prof. Alisa Miniotaitė holds a dual role as Associate Professor and Head of Leadership Program at ISM University of Management and Economics. She is also the Founder of ALISA MANAGEMENT LABORATORY, a certified ICC coaching trainer for the Baltic states, and a member of Academy of Management and International Leadership Association. Her work spans academic leadership, corporate consulting, and media engagement, including hosting the radio show Leader's Dilemma on Žinių radijas and providing regular commentaries for Baltic news portals. Education: PhD in Management (2013) from ISM University of Management and Economics Research Focus: Leadership development Organizational behavior HR innovation through AI Employee-employer dynamics Key Projects: Principal Investigator for the Experiment EU-funded project (2020-2022), developing an AI-driven HR platform Co-developed semantic CV analysis algorithms Publications: Over 20 peer-reviewed articles and books on leadership, AI applications, and organizational health Notable works include Organizational Diseases and Their Treatment (2023) and Authentic Leadership Impact (2013 doctoral work) Grants: Secured €66,796 for ISM through the Experiment project Labs/Teams: ALISA MANAGEMENT LABORATORY – focuses on leadership training and organizational consulting

• Management
• Leadership Development
• Organizational Behavior
• +3 more

Edward J. Miller, MD, PhD is a Professor of Medicine and Radiology & Biomedical Imaging at Yale School of Medicine. Currently serving as Vice Chief of Cardiovascular Medicine (Education) and Director of the Nuclear Cardiology Lab at Yale-New Haven Hospital, he leads the Cardiology Fellowship Program while maintaining active research in infiltrative cardiomyopathies like cardiac sarcoidosis and amyloidosis. BS - University of Notre Dame, Preprofessional Studies (1994) MD - Loyola-Stritch School of Medicine (1999) PhD - Yale, Investigative Medicine (2008) His work integrates nuclear cardiac imaging with artificial intelligence to improve diagnosis accuracy and treatment response monitoring. Recent studies focus on AI-enhanced body composition analysis from CT scans, race/sex-specific epicardial fat thresholds, and HEART score automation using GPT-4 technology. As a NIH/NHLBI K08 award recipient and Alpha Omega Alpha inductee, Dr. Miller has received multiple honors including the American College of Cardiology Fellowship and American Society of Nuclear Cardiology Fellowship . His military service includes two national awards from the United States Navy. Contact: edward.miller@yale.edu | 203.785.7191 (Clinical) | PO Box 208017, New Haven, CT 06520-8017

• Cardiology
• Nuclear Cardiology
• Infiltrative Cardiomyopathies
• +3 more

Rudolf Uher is a Professor of Psychiatry at Dalhousie University, holding academic appointments in the Department of Psychiatry, Department of Community Health and Epidemiology, Department of Psychology and Neuroscience, and Department of Medical Neuroscience. He is affiliated with the Faculty of Medicine and leads research initiatives such as the Canadian Depression Research and Intervention Network (CDRIN-Maritime) and the FORBOW cohort study. His work focuses on early interventions for mental disorders, psychiatric genetics, and personalized treatment strategies. Education: MD: Charles University PhD: Charles University CCT: King’s College London Research Interests: Dr. Uher investigates early interventions to prevent psychosis, depression, and bipolar disorder. His studies explore pharmacogenetics, gene-environment interactions, and biomarkers for personalized treatment. He also examines the classification of psychopathology and developmental trajectories of mental disorders. Awards: Max Hamilton Memorial Prize (2014) Canada Research Chair in Early Intervention in Psychiatry (2012) Robert W. Kerwin Prize in Psychopharmacology (2011) Denis Hill Prize (2009) Grants & Leadership: Leads the FORBOW study (offspring of parents with mental illness) and the SWELL intervention trial. Collaborates with WHO on mental disorder classifications and serves as Associate Editor for Depression and Anxiety . Labs/Teams: Co-leads the Pharmacogenetics work package of the NEWMEDS project and directs the CDRIN-Maritime hub for clinical depression research.

• Psychiatric Genetics
• Pharmacogenetics
• Early Interventions in Psychiatry
• +7 more

Thomas Issekutz, MD, is a Professor in the Departments of Pediatrics, Medicine, Microbiology & Immunology, and Pathology at Dalhousie University, affiliated with the IWK Health Centre’s Division of Immunology. His research focuses on immune dysregulation in genetic disorders, T cell biology, and clinical applications of immunology. He has contributed to national guidelines on immunoglobulin therapy and immunodeficiency management. His work spans inborn errors of immunity, rheumatoid arthritis, and pediatric immunology. Research interests include mechanisms of immune dysfunction in SCID, IRAK-4 deficiency, and Prolidase deficiency, as well as therapeutic interventions like high-dose IVIG. He has led studies on viral-induced immune responses and chemokine receptor roles in T cell trafficking. His clinical expertise includes managing complex immunodeficiency cases and guiding treatment strategies. Publications emphasize translational research, such as exome sequencing applications, interferon pathway analysis in autoimmune diseases, and biomarkers for drug response in rheumatoid arthritis. His work bridges basic immunology with clinical practice, impacting diagnostic and therapeutic approaches for rare immune disorders.

• Immunology
• Pediatric Immunology
• Autoimmune Disorders
• +3 more

Majid Fotuhi is an Adjunct Professor at George Washington University, specializing in neurology, memory, and Alzheimer’s disease prevention. His career includes roles as an instructor at Massachusetts General Hospital and an Assistant Professor at Johns Hopkins Hospital. He holds a Ph.D. in Neuroscience (Johns Hopkins University, 1992) and an M.D. from Harvard Medical School (1997). His research focuses on brain rehabilitation, neuroplasticity, and cognitive enhancement. He developed the 12-week “Brain Fitness Program,” integrating lifestyle changes with neurofeedback to improve memory and cognitive function in the elderly and patients with MCI. His work spans neurodegenerative diseases, obesity’s impact on brain structure, and the neurobiological effects of SARS-CoV-2. Key contributions include studies on NSAID-antioxidant combinations for cognitive protection (Cache County Study) and the role of omega-3 fatty acids in dementia prevention. His recent work explores post-COVID neurological effects and concussion recovery protocols. Publications span peer-reviewed journals like Nature , Neurology , and Alzheimer’s and Dementia . He founded NeuroGrow Brain Fitness Center, emphasizing personalized programs for cognitive health. His research bridges clinical practice and neuroscience to address aging-related cognitive challenges.

• Memory
• Neurodegenerative Diseases
• Neuroplasticity
• +3 more

Bryan Spring is an Associate Professor in the Department of Physics at Northeastern University's College of Science, where he leads the Spring Research Group focused on bridging biophysics, biomedical optics, and cancer biology. His work targets micrometastases left behind by standard cancer therapies through optical spectroscopic imaging and photophysics to visualize and eliminate residual tumors that lead to recurrence. Spring's research interests center on developing precision photomedicine approaches that address tumor heterogeneity, drug resistance, and molecular mechanisms of treatment escape. His group has pioneered tumor-targeted, activatable photoimmunotherapy (taPIT) that uses near-infrared light activation of molecular-targeted chromophores to selectively damage drug-resistant cancer cells while minimizing side effects. This approach enables microscopic-resolution 'optical biopsy' for identifying drug-resistant cancer cell deposits without invasive surgeries. His recent publications demonstrate a strong trend toward developing multicolor in vivo microendoscopy tools (hyperspectral, lifetime-resolved, and FRET imaging), real-time image analysis software, and molecular-targeted probes. The work spans from fundamental optical engineering to translational cancer research, with a particular focus on ovarian cancer treatment and overcoming drug resistance through photomedicine approaches. Scientific awards include the prestigious Smith Family Awards Program for Excellence in Biomedical Research (2017) and being selected as a Scialog Fellow for Advancing BioImaging (2021). His students have consistently won awards at major conferences, including multiple Poster of Excellence awards at the International Photodynamic Association World Congress. Professor Spring has secured significant research funding including an NIH-NCI R01 award ($3.2M), a Physical Sciences Oncology Network grant (~$2.7M), and an NCI R21 concept grant (~$0.5M). He maintains active collaborations with leading institutions including MD Anderson Cancer Center, Moffitt Cancer Center, Duke University, and Cornell University, as well as industry partners like Cellaria Bio. The Spring Research Group operates state-of-the-art facilities for developing precision photomedicine technologies, including custom femtosecond fiber lasers, GPU-accelerated hyperspectral image processing systems, and low-cost LED arrays for light-activated therapy. The lab's interdisciplinary team combines expertise in physics, optics, cancer biology, and computational imaging to advance next-generation cancer treatment approaches.

• Biophysics
• Biomedical Optics
• Cancer Biology
• +7 more

Dr Sally Lord is a Senior Research Fellow at the NHMRC Clinical Trials Centre, University of Sydney's Sydney Medical School. Her research focuses on epidemiology, clinical trial design, biomarker development, and evidence-based medicine. She specializes in evaluating diagnostic tests, clinical trial methodologies, and cancer outcomes. Dr Lord collaborates extensively on studies involving breast, ovarian, and lung cancers, with a focus on metastasis detection, treatment efficacy, and patient survival analysis. Her work includes population-based health record linkage studies and systematic reviews to assess clinical practices. She has contributed to guidelines for diagnostic test evaluation and clinical trial design, emphasizing patient-centered outcomes and healthcare policy. Dr Lord’s research also addresses challenges in oncology, such as biomarker validation, therapeutic response prediction, and cost-effectiveness of imaging strategies. Publications highlight her expertise in cancer epidemiology, clinical trial methodologies, and translational research. She is a key contributor to international collaborations, including studies on ovarian cancer maintenance therapy, metastatic breast cancer survival trends, and biomarker-driven treatment strategies.

• Epidemiology
• Clinical Trials
• Biostatistics
• +3 more

Dr James Ashton is an Associate Professor at the University of Southampton, holding affiliations with the Institute for Life Sciences, BiOmics, Human Genetics and Genomic Medicine, and the Institute of Developmental Sciences. His research focuses on precision medicine for inflammatory bowel disease (IBD), utilizing genomic and big data approaches to transform pediatric patient care through personalized diagnostics and therapeutic strategies. His primary research interests center on Inflammatory Bowel Disease, Paediatrics, Big Data analytics, Genomics, and Nutritional science. This work spans clinical, translational, and basic science domains, with emphasis on developing data-driven tools for disease prediction, stratification, and treatment optimization. Current projects integrate whole exome sequencing, methylome analysis, and machine learning to address critical gaps in pediatric IBD management. Analysis of his 2022-2025 publications reveals a consistent focus on genomic biomarkers (particularly NOD2), pharmacogenomics of thiopurines, and machine learning applications for IBD subtyping. His work leverages large clinical datasets to investigate treatment access disparities, disease burden quantification, and stricturing phenotype prediction, establishing a clear trajectory toward data-informed clinical decision-making in pediatric gastroenterology. Scientific Awards NIHR Advanced Fellowship Dr Ashton actively supervises PhD students including Zachary Green and Fernando Vazquez Lopez in Human Development & Health research. His work receives funding from the European Society for Clinical Nutrition and Metabolism (metabolomics project), Guts UK (PAIR-network development), and the European Society for Paediatric Research (NOD2 analysis), demonstrating sustained competitive grant support for pediatric IBD innovation. As core faculty within Southampton's interdisciplinary research ecosystem, he contributes to multiple collaborative groups including the Institute for Life Sciences and Human Genetics and Genomic Medicine, where his team develops genomic biomarkers and big data frameworks to advance precision medicine implementation in inflammatory bowel disease.

• Inflammatory Bowel Disease
• Paediatrics
• Big Data
• +2 more

Prof. Igle Jan de Jong is a Professor at the University of Groningen's Faculty of Medical Sciences, affiliated with the Personalized Cancer Treatment (PCT) and BRIDGE research groups at the UMCG. He holds a visiting professorship at Pavlov First Saint Petersburg State Medical University since 2020. He obtained a University Teaching Qualification from the University of Groningen in 2014. His research focuses on prostate cancer, medical imaging (particularly PET/CT), and urological oncology. Key interests include biomarker analysis, surgical outcomes, and comparative effectiveness of treatment modalities. His work addresses clinical challenges in prostate cancer management, such as treatment protocols and imaging-guided therapies. Recent publications (2025) explore biomarkers for radium-223 efficacy, AI-driven prostate cancer progression prediction, and surgical outcomes under minimum volume standards. He co-leads the RECOVER study comparing radiation therapy and prostatectomy for high-risk prostate cancer. Prof. de Jong has supervised 11 academic works and contributes to multidisciplinary initiatives like the Prostaatcentrum Noord-Nederland. His research aligns with UN SDGs related to health and well-being.

• Prostate Cancer
• Medical Imaging (PET/CT)
• Urological Oncology
• +3 more

Associate Professor Cindy Thamrin is an Adjunct Associate Professor at the University of Sydney's School of Medical Sciences and Principal Research Scientist at the Australian Department of Health and Aged Care. She holds memberships in major respiratory societies including the American Thoracic Society and European Respiratory Society. Education: Bachelor of Science/Engineering (BSc/BE) PhD in Respiratory Physiology (University of Western Australia) Research Focus: Advanced lung function testing, home telemonitoring of COPD and asthma, and predictive analytics for respiratory outcomes. Her work combines biomedical engineering principles with clinical medicine to improve diagnostics and therapies for airway diseases. Awards & Recognition: Ann Woolcock Young Investigator Award (2013) John Read Prize for Physiology Research (2005) Multiple grants from NHMRC, ATS, and Swiss National Science Foundation Grants & Projects: Telemonitoring of lung function variability in COPD/asthma (NHMRC 2015) EXHALYZER D Pulmonary Function Testing equipment grant (NHMRC 2014) International Collaboration: Partnering with Politecnico di Milano on variability analysis of home lung monitoring data.

• Respiratory Medicine
• Lung Function Testing
• Chronic Obstructive Pulmonary Disease (COPD)
• +5 more